Table 3. Patient satisfaction responses at 12 months posttreatment with calcium hydroxylapatite for human immunodeficiency virus–associated facial lipoatrophy (N=100*) [22]

 

Question	Yes (%)	No (%)
Would you recommend calcium hydroxylapatite treatment?	97 (99.0)	1 (1.0)
Has the calcium hydroxylapatite treatment been beneficial to you?	98 (100.0)	0 (0.0)
Do you feel more attractive since receiving calcium hydroxylapatite treatment?	97 (99.0)	1 (1.0)
Is your emotional well-being better since receiving calcium hydroxylapatite?	95 (96.9)	3 (3.1)
Do you have more confidence in your appearance since receiving calcium hydroxylapatite?	97 (99.0)	1 (1.0)

*Two patients did not return for the 12-month follow-up visit.

Adapted with permission from Silvers SL et al, Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability, Plast Reconstr Surg. 2006; 118:34S-45S [22].